An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
2 other identifiers
interventional
N/A
1 country
1
Brief Summary
To establish the relationship between the oral dose of zidovudine (AZT) and its hematologic toxicity. AZT has preliminarily been shown to decrease significant events and death in a group of AIDS / Pneumocystis carinii pneumonia (PCP) and AIDS related complex (ARC) patients followed at this time for a limited period. If these data withstand further follow-up, it appears that AZT is a potential antiretroviral agent that may have application in the use of all stages of HIV disease. At this time the optimal dose that will not cause significant toxicity is not known. If this drug has widespread application, it becomes imperative to further study both the dose and the toxicity. Patients with documented HIV viremia and who are well will be evaluated in a dose-escalating protocol for toxicity, persistent viremia, evidence of improvement of immune dysfunction, and the development of further manifestation of HIV disease. Drug levels will be monitored and correlated with the toxicity and viremia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 1999
CompletedFirst Posted
Study publicly available on registry
August 31, 2001
CompletedJune 24, 2005
February 1, 1995
November 2, 1999
June 23, 2005
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients must have HIV reactivity.
- Patients must belong to one of the following three groups according to the CDC classification:
- IIB - including only those patients with autoimmune thrombocytopenia (platelet count = or \< 100000 platelets/mm3).
- OR Lymphopenia (lymphocyte count = or \< 1000 cells/mm3).
- OR Helper cell lymphopenia (helper cells \< the mean of normals).
- OR CDC classification III or IV-C2.
- Patients with = or \< involuntary 10 percent weight loss in the last 6 months.
- ECOG performance status 0 or 1.
- Weigh 70 kg + or - 15 kg in order to standardize the g/kg dosing.
- Positive antibody for HIV by an ELISA test kit. If the ELISA is negative, then eligibility will be confirmed by second confirmatory test, i.e., immunoblot.
You may not qualify if:
- Co-existing Condition:
- Patients with the following are excluded:
- AIDS or the CDC classification stage IV except stage IV-C2.
- HIV antibody negative by immunoblot.
- Persistent fevers of \> 38.5 degrees C.
- Persistent diarrhea undiagnosed \> 1 month.
- Involuntary weight loss of \> 10 percent in the 6 months prior to study entry.
- ECOG performance status of 2, 3, or 4.
- Class IV-C2 with prior history of:
- Multidermal herpes zoster.
- Oral candidiasis on more than one occasion.
- Tuberculosis.
- Concurrent Medication:
- Excluded:
- Other antiretroviral agents.
- +26 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Glaxo Wellcomelead
Study Sites (1)
Glaxo Wellcome Inc
Research Triangle Park, North Carolina, 27709, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 2, 1999
First Posted
August 31, 2001
Last Updated
June 24, 2005
Record last verified: 1995-02